Compare Tango Therapeutics Inc. (TNGX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.53 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 19.3× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard Intermediate Term Corporate Bond ETF for 64 Days on average.
| TNGX | VCIT | |
|---|---|---|
Market Cap | $3.74B | $72.20B |
Volume | 3,438,781 | 13,245,117 |
Sector | Health | Fixed Income |
52-Week High | $32.90 | $84.82 |
52-Week Low | $7.50 | $77.98 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $78.48, down 0.03% on the day. The technical outlook is mixed with a bullish overall signal but bearish moving averages, while fundamentals are supported by a 4.8% yield and low 0.03% expense ratio. Recent news highlights institutional buying and favorable comparisons to peer bond ETFs.
The outlook for VCIT is positive for income-focused investors seeking corporate bond exposure with low costs. Key opportunities include attractive yield and institutional interest, while risks involve interest rate sensitivity and credit spread volatility in the corporate bond market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
